Drug Trial Radar · NCT02158858
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
336
Actual
Start
Jul 16, 2014
Primary completion
Jan 9, 2025
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Constellation PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- The Leukemia and Lymphoma Society
- First posted
- Jun 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms. Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Conditions
- Myelofibrosis
- Leukemia, Myelocytic, Acute
- Myelodysplastic/Myeloproliferative Neoplasm
- Myelodysplastic Syndrome (MDS)
- Preleukemia
- Primary Myelofibrosis
- Myeloproliferative Disorders
- Bone Marrow Disease
- Hematological Disease
- Precancerous Conditions
- Neoplasms
- Leukemia
- Neoplasms by Histologic Type
- Essential Thrombocytosis
Interventions
PelabresibDrug
CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
RuxolitinibDrug
Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Frequency of Dose-limiting Toxicities (DLTs)Time frame: Up to 21 days
- Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at Week 24Time frame: Week 24 (Cycle 9 Day 1)
- Phase 2 (Cohorts 1A and 2A): Number of Participants Enrolled as Transfusion Dependent (TD) With Conversion Rate From Red Blood Cell (RBC) Transfusion Dependence (TD) to Transfusion Independence (TI)Time frame: Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)
- Phase 2 (Arm 4): Number of Participants With Complete Hematological Response (CHR) RateTime frame: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)
Locations
48 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona
UCLA Medical Center
Los Angeles, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Northwestern University - Lurie Comprehensive Cancer Center
Chicago, Illinois
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Washington University School of Medicne Neuromuscular Division Department of Neurology Research
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
ICAHN School of Medicine at Mount Sinai
New York, New York
Weill Medical College and New York Presbyterian Hospital
New York, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
ZNA Stuyvenberg Antwerpen
Antwerp, Belgium
UZ Leuven - Campus Gasthuisberg
Leuven, Viaams Braban, Belgium
AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan
Bruges, West-Vlaanderen, Belgium
University of Alberta Hospital
Edmonton, Alberta, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
CHU - Hopital Saint Louis - Centre D'Investigations Clinique
Paris, France
Institut de cancérologie du Gard - Hematologie clinique
Nîmes, Gard, France
CHRU de Lille - Hopital Claude Huriez
Toulouse, Haute-Garonne, France
CHRU de Lille - Hopital Claude Huriez - Maladies du Sang
Lille, Hauts-de-France, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Universitätsklinikum Leipzig AöR
Leipzig, Saxony, Germany
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
AOU Maggiore della Carità
Novara, Italy
Institue of Hematology "L. and A. Seràgnoli"
Bologna, Emilia-Romagna, Italy
Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini
Rimini, Emilia-Romagna, Italy
AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can
Genoa, Liguria, Italy
Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
Milan, Lombardy, Italy
IRCCS Policlinico San Matteo, Università degli studi di Pavi
Pavia, Lombardy, Italy
Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon
Varese, Lombardy, Italy
Maastricht University Medical Center
Maastricht, Limburg, Netherlands
VUmcResearch B.V.
Amsterdam, North Holland, Netherlands
Erasmus Universitair Medisch Centrum Rotterdam
Rotterdam, South Holland, Netherlands
Instytut Hematologii i Transfuzjologii w Warszawie
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, Poland
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.